• to understand the deregulation of the signalling pathway in oncogenesis
• to discover and to validate new targeted therapy
• to develop new biotechnology tools for basic and translational research (nanomedecine, proteomics)

As Chair of the program, “Oncogenic signalling and new therapeutic targets"at the Cancéropôle Grand Sud Ouest, he is charge of the scientific animation of the program. This program includes 52 basic research teams, 15 teams of clinical research investigators and a private company.

As Director of Research at Comprehensive Cancer Centre, Claudius REGAUD Institute, he is in charge of the management of clinical, translational and basic research. His main objectives are to favour translational research by bringing together clinicians and basic scientists. He has structured three translational research programs on breast cancer, clinical pharmacology and radiotherapy that have been successful in translating new therapeutic concepts to the clinic. He has also been at the origin of the building of core facilities for molecular analysis of the tumour.

As Head of the Cancer Research Network of Toulouse, he is responsible for setting up oncology research at the cancer campus in Toulouse.

Expertise

INSERM : Member of the National Scientific Council (since 2003), Member of “commission Avenir” (since 2004), scientific expert (since 2002)

French Ministry of research and new technologies: scientific expert (since 2002)

French National Cancer Institute : member of the international scientific advisory board (since 2005)

Cancéropôle Grand Sud Ouest : member of the Scientific Committee

Ligue Contre le Cancer: Chair of the scientific committee of Midi Pyrénées (since 2004)

Member of the scientific council of the Ligue Nationale de Lutte Contre le Cancer (from 1999 to 2002), expert (since 1999)

Reviewer for many international journals : Cancer Res., Oncogene, J Biol. Chem, BBRC, Cancer Letters, Endocrinology, BMC Cancer…

Consultant for pharmaceutical companies : P.FABRE Médicaments, ASTRA ZENECA, DEBIOPHARM

Main publications

91 publications and five licences from 1981 to 2006, the 10 main original publications are cited since 2000

Chen, Z., J. Sun, A. Pradines, G. Favre, J. Adnane, and S.M. Sebti, Both farnesylated and
geranylgeranylated RhoB inhibit malignant transformation, induce apoptosis and suppress
human tumor growth in nude mice. J. Biol. Chem., 2000. 275, 17974-17978.

Baron R., Fourcade E., Lajoie-Mazenc I., Allal C., Barbaras R., Favre G., Faye J. C., Pradines
A. RhoB prenylation is driven by the three carboxyl-terminal aminoacid : evidenced in vivo by
an anti-farnesyl cysteine antibody Proc. Natl. Acad. Sci. USA, 2000. 97,

Ader, I., Toulas, C., Dalenc, F., Delmas, C., Bonnet, J., Cohen-Jonathan, E., and Favre, G.
RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing postmitotic
cell death. Oncogene, 21: 5998-6006, 2002.

Doisneau-Sixou, S. F., Cestac, P., Chouini, S., Carroll, J. S., Hamilton, A. D., Sebti, S. M.,
Poirot, M., Balaguer, P., Faye, J. C., Sutherland, R. L., and Favre, G. Contrasting effects of
prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen
receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology, 144: 989-998, 2003.

Boutonnet, C., Boijoux, O., Bernat, S., Kharrat, A., Favre, G., Faye, J. C., and Vagner, S.
Pharmacological-based translational induction of transgene expression in mammalian cells.
EMBO Rep., 5: 721-727, 2004.

Mazieres, J., Antonia, T., Daste, G., Muro-Cacho, C., Berchery, D., Tillement, V., Pradines, A.,
Sebti, S., and Favre, G. Loss of RhoB expression in human lung cancer progression. Clin
Cancer Res., 10: 2742-2750, 2004.

Milia, J., Teyssier, F., Dalenc, F., Ader, I., Delmas, C., Pradines, A., Lajoie-Mazenc, I., Baron,
R., Bonnet, J., Cohen-Jonathan, E., Favre, G., and Toulas, C. Farnesylated RhoB inhibits
radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication.
Cell Death.Differ., 12: 492-501, 2005.

Tilkin-Mariame, A. F., Cormary, C., Ferro, N., Sarrabayrouse, G., Lajoie-Mazenc, I., Faye, J.
C., and Favre, G. Geranylgeranyl transferase inhibition stimulates antimelanoma immune
response through MHC class I and costimulatory molecule expression. FASEB J,. 19:1513-
1515, 2005.

Canguilhem, B., Pradines, A., Baudouin, C., Boby, C., Lajoie-Mazenc, I., Charveron, M. and
Favre, G. RhoB protects human keratinocytes from UVB-induced apoptosis through EGF
receptor signaling. J. Biol. Chem.;280:43257-63. 2005.

Skuli, N., Monferran, S. , Delmas, C., Lajoie-Mazenc; I. , Favre, G. , Toulas, C., Cohen-
Jonathan-Moyal, E. Activation of RhoB by hypoxia controls HIF-1stabilization through GSK-3
in glioblastoma. Cancer Res. 66:482-9, 2006